Inflammatory Bowel Disease Registry
Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment
Quotient’s somatic genomics platform technology will be used to develop the treatment
Inizio announced as headline sponsor for 2026 Communiqué Awards
The PMGroup Awards celebrate excellence in health communications
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Abivax shares positive late-stage results for obefazimod in ulcerative colitis
Inflammatory bowel disease affects nearly one in every 100 people in the US
Communiqué 2025: celebrating excellence in healthcare communications
This year’s Awards, held at the Grosvenor House Hotel in London on 3 July, included 30 categories
EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive
Kostaive is designed to instruct the body to make more mRNA to boost immune response
WHO urges US to ‘reconsider’ withdrawal from global health organisation
President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises
Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines
The combined vaccine approach could simplify immunisation practices and lead to higher uptake
Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults
Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19
Seven strategic steps to enhance patient recruitment & retention in your influenza studies
The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...